Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to confirm the clinical benefit rate(CBR) in the use of Fulvestrant for estrogen receptor positive, HER2 negative Japanese postmenopausal advanced and recurrence breast cancer

Next Previous
Trial Profile

Study to confirm the clinical benefit rate(CBR) in the use of Fulvestrant for estrogen receptor positive, HER2 negative Japanese postmenopausal advanced and recurrence breast cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 22 May 2021 Status changed from recruiting to discontinued.
  • 04 Feb 2014 Actual initiation date changed from 1 Nov 2013 to 20 Jan 2014 as per University Hospital Medical Information Network Japan (UMIN000012153)
  • 08 Nov 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top